title: PST-2238 Sigma-Tau.
abstract: Sigma-Tau is developing PST-2238, the prototype of a new class of hypertensive steroidal ATPase modulators, for the potential treatment of hypertension [169159]. Phase II trials were ongoing in early 2002 [441505].
authors.affiliation: PGIMER, Department of Internal Medicine, Chandigarh, 160012, India. drsjain@glide.net.in
authors.forename: Sanjay
authors.initials: S
authors.lastname: Jain